March 12th 2025
Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.
March 9th 2025
Exosomes, polymeric nanoparticles, and DNA nanostructures offer many potential advantages.
February 17th 2025
The approval makes Evrysdi the first and only tablet for treating spinal muscular atrophy.
February 8th 2025
European biopharma companies are looking beyond GLP-1s.
February 7th 2025
Increasing API and formulation complexity and new delivery strategies are driving innovations in taste-masking.
Injecting Highly Viscous Drugs
The author reviews the challenges in delivering macromolecule biologics.
Measuring syringe plunger force using a texture analyzer instrument
Measuring syringe plunger force using a texture analyzer instrument.
Considerations in Developing Sublingual Tablets—An Overview
This review highlights relevant physicochemical drug properties and formulation design considerations critical to quality and performance of the sublingual tablets.
WHO Promotes International Collaboration for Generic Drug Approvals
The European Union takes the lead in a global pilot project on the marketing approval of generic medicines, highlighting the challenges of achieving consensus among different nations.
First Biosimilar Application Kicks Off Legal Battle
Amgen is suing Sandoz over Sandoz's biosimilar application for filgrastim.
SAFC Introduces New Protein Quality Supplement for Optimized Biologics Production
Sigma-Aldrich's custom manufacturing services business unit, SAFC, has launched a new protein quality supplement for biological drug production, including biosimilars.
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
Bristol-Myers Squibb announced that they have reached an agreement with F-star Alpha, giving BMS the exclusive option to acquire F-star's HER2-targeted breast and gastric cancer treatment.
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
The divestment will create the number two player in the global influenza vaccine industry.
GSK Accelerates Ebola Vaccine Development
GSK's investigational Ebola vaccine is in Phase I safety trials.
J&J Speeds Ebola Vaccine Development and Expands Production
Johnson& Johnson is collaborating with WHO and others on clinical testing, development, production, and distribution of an Ebola vaccine.
EMA Works to Speed Up Ebola Treatment
The agency recommends that companies developing drugs to treat Ebola apply for orphan drug designation.
Evaluating Cross-Contamination Risk of Highly Potent APIs
Manufacturers using highly potent APIs must examine cross-contamination routes and determine acceptable limits.
IDT Biologika Certifies Facility to Fill and Lyophilize Biologics and Vaccines
IDT Biologika completes large-scale biologics finishing facility in Dessau, Germany.
Focus on Biosimilars
The total market for biopharmaceuticals in 2013 was $36.8 billion according to Kalorama Information. Meanwhile, Frost & Sullivan estimates that the biosimilars market, which it pegged at just $1.2 billion in 2013, will grow to $23 billion in 2019, or more than 20-fold increase.
Micronization as a Bioavailability Enhancement Tool
Pharmaceutical Technology Europe spoke with Piero Iamartino, R&D director at Micro-Macinazione, about the role of micronization in pharmaceutical manufacturing.
Milan API Producer Opens High-Potent API Plant
LABOCHIM SpA completes construction on multipurpose high-potent API plant in Milan.
Biopharma Manufacturers Respond to Ebola Crisis
Demand for new therapies and vaccines spotlights production challenges.
Solving Poor Solubility with Amorphous Solid Dispersions
Weighing the pros and cons of hot-melt extrusion and spray drying.
Harmonizing Marketing Approval of Generic Drugs in Europe
Regulatory agencies in Europe are working to harmonize the marketing approval pathway of generic medicines.
New Technologies Enhance the Formulation of Highly Potent Drugs
Advances in solid and liquid formulation techniques are providing more options.
NIH Seeks to Improve Vaccine Response with New Adjuvants
NIH seeks new therapeutic products to bolster the protective properties of vaccines.
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
Partnership is awarded for licensing of low-cost vaccine for the treatment of bacterial meningitis.
USP Supports WHO Biologics Naming Proposal
USP expresses its support for a consensus-based global approach to the naming of biologics.
Catalent and Cingulate Therapeutics to Collaborate on New ADHD Formulation
Formulation will utilize Catalent?s OSDrC OptiDose multicore drug-delivery platform.
CALIXAR Collaborates with VirPath to Develop H1N1 Vaccine
CALIXAR and VirPath use new manufacturing techniques to create a vaccine for the pandemic flu, influenza A (H1N1), available in 2015.
Pandemic Vaccine Facility Dedicated in Texas
Texas A&M dedicates national pandemic influenza vaccine manufacturing facility.
Need for Particle Engineering Increases
Micronization and other processes are used to obtain optimal particle characteristics for pulmonary and oral solid-dosage delivery.
Generic Pharmaceutical Association Reports Record Cost Savings
A GPhA report says generic drugs saved the US health system $239 billion in 2013.
Molecular Profiles Expands Capsule Capability
Molecular Profiles has expanded its capsule filling capability following significant investment into new equipment at its clinical manufacturing site in the United Kingdom.
FDA Approves Phase 1 Clinical Trials for NewLink Genetics' Ebola Vaccine
FDA gives NewLink Genetics approval to proceed to Phase 1 clinical studies of Ebola vaccine.